Lam, S W <br/><br/>
Paclitaxel and bevacizumab with or without capecitabine   as first-line treatment for HER2-negative locally recurrent   or metastatic breast cancer: a multicentre, open-label,   randomised phase 2 trial.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Dec 2014 
 - 3077-88 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2014.10.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Capecitabine<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Paclitaxel--administration & dosage<br/>Treatment Outcome<br/>Triple Negative Breast Neoplasms--drug therapy